A preference study: calcium acetate tablets versus gelcaps in hemodialysis patients. (Research Brief).: An article from: Nephrology Nursing Journal
Book Details
PublisherJannetti Publications, Inc.
ISBN / ASINB0009FT0YS
ISBN-13978B0009FT0Y5
AvailabilityAvailable for download now
Sales Rank12,448,574
MarketplaceUnited States 🇺🇸
Description
This digital document is an article from Nephrology Nursing Journal, published by Jannetti Publications, Inc. on August 1, 2002. The length of the article is 1691 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
From the author: End stage renal disease (ESRD) patients are frequently noncompliant with phosphate binder therapy. This noncompliance may lead to uncontrolled hyperphosphatemia, resulting in an increased risk of mortality via the development of serious comorbid conditions. A new gelcap form of calcium acetate has been introduced for control of hyperphosphatemia. This single center, unblinded study compared calcium acetate tablets versus calcium acetate gelcaps with regards to patient preference and ease of swallowing. Twenty-two patients were randomized to receive 1 day of treatment with calcium acetate tablets, followed by 1 day of treatment with calcium acetate gelcaps, or vice versa. Following completion of the treatment period, the patients were given a questionnaire to complete that asked them to compare their experience with both treatments. Twenty patients completed the study. Eighteen patients preferred the gelcap to the tablet in all preference categories. The same 18 patients responded that the gelcap was easier to swallow than the tablet. Because of the evidence documenting the noncompliant behavior of ESRD patients with respect to their binder therapy, efforts made to give the patients a more satisfying alternative can aid in improving compliance.
Citation Details
Title: A preference study: calcium acetate tablets versus gelcaps in hemodialysis patients. (Research Brief).
Author: Mark R. Kaplan
Publication:Nephrology Nursing Journal (Refereed)
Date: August 1, 2002
Publisher: Jannetti Publications, Inc.
Volume: 29 Issue: 4 Page: 363(3)
Distributed by Thomson Gale
From the author: End stage renal disease (ESRD) patients are frequently noncompliant with phosphate binder therapy. This noncompliance may lead to uncontrolled hyperphosphatemia, resulting in an increased risk of mortality via the development of serious comorbid conditions. A new gelcap form of calcium acetate has been introduced for control of hyperphosphatemia. This single center, unblinded study compared calcium acetate tablets versus calcium acetate gelcaps with regards to patient preference and ease of swallowing. Twenty-two patients were randomized to receive 1 day of treatment with calcium acetate tablets, followed by 1 day of treatment with calcium acetate gelcaps, or vice versa. Following completion of the treatment period, the patients were given a questionnaire to complete that asked them to compare their experience with both treatments. Twenty patients completed the study. Eighteen patients preferred the gelcap to the tablet in all preference categories. The same 18 patients responded that the gelcap was easier to swallow than the tablet. Because of the evidence documenting the noncompliant behavior of ESRD patients with respect to their binder therapy, efforts made to give the patients a more satisfying alternative can aid in improving compliance.
Citation Details
Title: A preference study: calcium acetate tablets versus gelcaps in hemodialysis patients. (Research Brief).
Author: Mark R. Kaplan
Publication:Nephrology Nursing Journal (Refereed)
Date: August 1, 2002
Publisher: Jannetti Publications, Inc.
Volume: 29 Issue: 4 Page: 363(3)
Distributed by Thomson Gale
